Adil Vural1, Amy Attaway2, Nicole Welch3, Joe Zein4, Srinivasan Dasarathy5. 1. Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, USA. 2. Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA. 3. Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, USA; Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, USA. 4. Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, USA; Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA. 5. Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, USA; Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, USA. Electronic address: dasaras@ccf.org.
Abstract
BACKGROUND & AIMS: There are very limited data on the healthcare burden of muscle loss, the most frequent complication in hospitalized cirrhotics. We determined the healthcare impact of a muscle loss phenotype in hospitalized cirrhotics. METHODS: The Nationwide Inpatient Sample (NIS) database (years 2010-2014) was analyzed. Search terms included cirrhosis and its complications, and an expanded definition of a muscle loss phenotype that included all conditions associated with muscle loss. In-hospital mortality, length of stay (LOS), post-discharge disposition, co-morbidities and cost during admission were analyzed. Univariate and multivariate analyses were performed to identify associations between a muscle loss phenotype and outcomes. Impact of muscle loss in cirrhotics was compared to that in a random sample (2%) of general medical inpatients. RESULTS: A total of 162,694 hospitalizations for cirrhosis were reported, of which 18,261 (11.2%) included secondary diagnosis codes for a muscle loss phenotype. A diagnosis of muscle loss was associated with a significantly (p < 0.001 for all) higher mortality (19.3% vs 8.2%), LOS (14.2 ± 15.8 vs. 4.6 ± 6.9 days), and median hospital charge per admission ($21,400 vs. $8573) and a lower likelihood of discharge to home (30.1% vs. 60.2%). All evaluated outcomes were more severe in cirrhotics than general medical patients (n = 534,687). Multivariate regression analysis showed that a diagnosis of muscle loss independently increased mortality by 130%, LOS by 80% and direct cost of care by 119% (p < 0.001 for all). Alcohol use, female gender, malignancies and other organ dysfunction were independently associated with muscle loss. CONCLUSIONS: Muscle loss contributed to higher mortality, LOS, and direct healthcare costs in hospitalized cirrhotics.
BACKGROUND & AIMS: There are very limited data on the healthcare burden of muscle loss, the most frequent complication in hospitalized cirrhotics. We determined the healthcare impact of a muscle loss phenotype in hospitalized cirrhotics. METHODS: The Nationwide Inpatient Sample (NIS) database (years 2010-2014) was analyzed. Search terms included cirrhosis and its complications, and an expanded definition of a muscle loss phenotype that included all conditions associated with muscle loss. In-hospital mortality, length of stay (LOS), post-discharge disposition, co-morbidities and cost during admission were analyzed. Univariate and multivariate analyses were performed to identify associations between a muscle loss phenotype and outcomes. Impact of muscle loss in cirrhotics was compared to that in a random sample (2%) of general medical inpatients. RESULTS: A total of 162,694 hospitalizations for cirrhosis were reported, of which 18,261 (11.2%) included secondary diagnosis codes for a muscle loss phenotype. A diagnosis of muscle loss was associated with a significantly (p < 0.001 for all) higher mortality (19.3% vs 8.2%), LOS (14.2 ± 15.8 vs. 4.6 ± 6.9 days), and median hospital charge per admission ($21,400 vs. $8573) and a lower likelihood of discharge to home (30.1% vs. 60.2%). All evaluated outcomes were more severe in cirrhotics than general medical patients (n = 534,687). Multivariate regression analysis showed that a diagnosis of muscle loss independently increased mortality by 130%, LOS by 80% and direct cost of care by 119% (p < 0.001 for all). Alcohol use, female gender, malignancies and other organ dysfunction were independently associated with muscle loss. CONCLUSIONS:Muscle loss contributed to higher mortality, LOS, and direct healthcare costs in hospitalized cirrhotics.
Authors: Elizabeth J Carey; Jennifer C Lai; Christopher Sonnenday; Elliot B Tapper; Puneeta Tandon; Andres Duarte-Rojo; Michael A Dunn; Cynthia Tsien; Eric R Kallwitz; Vicky Ng; Srinivasan Dasarathy; Matthew Kappus; Mustafa R Bashir; Aldo J Montano-Loza Journal: Hepatology Date: 2019-08-19 Impact factor: 17.425
Authors: Dong D Wang; Cindy W Leung; Yanping Li; Eric L Ding; Stephanie E Chiuve; Frank B Hu; Walter C Willett Journal: JAMA Intern Med Date: 2014-10 Impact factor: 21.873
Authors: John Guirguis; Jagpreet Chhatwal; Jaividhya Dasarathy; John Rivas; David McMichael; Laura E Nagy; Arthur J McCullough; Srinivasan Dasarathy Journal: Alcohol Clin Exp Res Date: 2015-10-25 Impact factor: 3.455
Authors: Kenneth E Covinsky; Robert M Palmer; Richard H Fortinsky; Steven R Counsell; Anita L Stewart; Denise Kresevic; Christopher J Burant; C Seth Landefeld Journal: J Am Geriatr Soc Date: 2003-04 Impact factor: 5.562
Authors: Jennifer C Lai; Puneeta Tandon; William Bernal; Elliot B Tapper; Udeme Ekong; Srinivasan Dasarathy; Elizabeth J Carey Journal: Hepatology Date: 2021-09 Impact factor: 17.298